Skip to main content

Table 1 Patient, tumour, and pre-treatment biopsy characteristics (43 samples used in prediction analysis)

From: The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis

Age: median (range) 49 (28–68)     
Menopausal status pre: 25 (58%) post: 9 (21%) na: 1 (2%) HRT: 8 (19%)  
Histological subtype lob: 6 (14%) duct: 34 (79%) duct/lob: 1 (2%) medull: 1 (2%) na: 1
ER status +: 29 (67%) -: 13 (30%) na: 1 (2%)   
HER-2 status +: 5 (12%) -: 36 (84%) na: 2 (5%)   
Inflamm infiltrate nil: 19 (44%) mild: 16 (37%) mod: 6 (14%) severe: 2 (5%)  
Grade 2: 18 (42%) 3: 24 (56%) na: 1 (2%)   
Percentage invasive tumour: median (range) 50 (20–95)     
Response pCR: 4 (9%)* cCR: 16 (37%) MRD: 3 (7%) PR: 8 (19%) NC: 12 (28%)
(*7 [16%] had no surgery) good: 23 (53%)    poor: 20 (47%)  
Clinical stage:      
Primary dimension (n)      
2.0–3.0 cm 15     
3.1–4.0 cm 7     
4.1–5.0 cm 9     
>5.0 cm 11     
Multifocal 1     
Median dimension (range) (cm) 4 (2–10)     
    ER + ER -  
Skin involvement (n) 2 HER2 + 4 (10%) 1 (2%)  
Inflammatory (n) 2     
   HER2 - 24 (56%) 12 (28%)  
Nodal involvement (n)     (2 na)  
N0 29     
N1 14     
N2 0     
NA 0     
  1. 'Postmenopausal' refers to patients not on HRT at diagnosis. Postmenopausal patients on HRT at diagnosis are listed under 'HRT'. 'Primary dimension' refers to the maximum tumour diameter (cm). 'Inflammatory infiltrate' score and 'median percentage invasive tumour' relate to values for the core used in prediction analysis. +, positive; -, negative; cCR, complete clinical response; duct, ductal; duct/lob, mixed ductal/lobular carcinoma; ER, oestrogen receptor; HRT, hormone replacement therapy; lob, lobular; medull, medullary; inflamm, inflammatory; mod, moderate; MRD, minimal residual disease; na, not available; NC, no change; pCR, complete pathological response; PR, partial response.